Last updated: February 20, 2026
What is Flurbiprofen?
Flurbiprofen is a non-steroidal anti-inflammatory drug (NSAID) used primarily for pain relief, inflammation reduction, and treatment of conditions such as arthritis and ocular inflammation. It is available in oral and topical formulations. Its chemical name is (RS)-2-(3-Fluorophenyl)propanoic acid. The drug was first introduced in the 1980s and has a market presence primarily in ophthalmology and rheumatology.
Market Overview and Sales Drivers
Current Market Size and Growth
- Global NSAID market size was valued at approximately $16.5 billion in 2021.
- Flurbiprofen accounted for an estimated niche within this, especially in ophthalmic indications.
- Projected CAGR (Compound Annual Growth Rate) for NSAIDs is around 3.2% from 2022–2027 [1].
Key Market Segments
| Segment |
Market Share |
Main Use Cases |
| Rheumatology |
45% |
Osteoarthritis, rheumatoid arthritis |
| Ophthalmology |
30% |
Postoperative inflammation, uveitis |
| Miscellaneous |
25% |
Dental pain, other inflammatory conditions |
Drivers of Growth
- Rising prevalence of osteoarthritis and rheumatoid arthritis.
- Advancements in ophthalmic drug delivery systems.
- Growing geriatric population globally.
Patent and Regulatory Landscape
Patent Status
- Original patents for flurbiprofen expired in the early 2000s.
- Several secondary patents exist around formulations, delivery methods, and specific indications.
- Companies are exploring new formulations—e.g., sustained-release, nanoparticle-based topical applications—to extend exclusivity.
Regulatory Approvals
- Approved by FDA for ophthalmic use (e.g., Voltarol FS in the US—although marketed under different brand names for NSAID eye drops).
- In the EU, marketed as ocufen for ocular inflammation.
- Limited approvals for oral pain management due to gastrointestinal side effects.
Competitive Landscape
| Major Players |
Notable Developments |
| Allergan (AbbVie) |
Ophthalmic formulations, recent licensing of NSAID new compounds |
| Novartis |
Focused on combination therapies |
| Generic manufacturers |
Large share post-patent expiry, offering cost-effective options |
R&D and Pipeline Trends
- Focused on improving bioavailability, reducing systemic side effects.
- Research into nanoformulations and targeted delivery methods.
- Development of combination drugs incorporating flurbiprofen with other anti-inflammatory agents.
Investment Considerations
Opportunities
- Niche ophthalmic applications with increasing demand.
- Potential for formulations with extended patent protection.
- Growth in OTC availability in emerging markets for pain relief.
Risks
- Patent expirations leading to generic competition.
- Safety concerns related to NSAID gastrointestinal and cardiovascular side effects.
- Regulatory hurdles for new formulations or indications.
Financial and Business Impacts
| Aspect |
Details |
| Revenue Potential |
Limited in broad NSAID markets; higher in niche indications |
| Cost of R&D |
Moderate, focused on formulation enhancement |
| Margins |
Generally lower in generic markets, higher with innovative formulations |
Limitations and Future Outlook
- Flurbiprofen’s market share is constricted by competition from other NSAIDs with established safety profiles, such as ibuprofen and naproxen.
- Label expansion into new indications could boost revenues but faces regulatory and clinical trial requirements.
- Strategic partnerships for formulation innovation present opportunities.
Key Takeaways
- Flurbiprofen operates mainly in niche ophthalmic and rheumatology segments.
- Market growth is driven by increasing chronic inflammatory conditions and ophthalmic needs.
- Patent expiry has led to widespread generic competition, impacting margins.
- Innovation in delivery methods and new formulations could extend its commercial viability.
- Regulatory pathways remain challenging but offer opportunities for formulation-based differentiation.
FAQs
What are the main indications for flurbiprofen?
Ophthalmic inflammation, post-surgical pain, osteoarthritis, and rheumatoid arthritis.
Is flurbiprofen available as an OTC drug?
In some markets, certain NSAIDs with flurbiprofen are OTC, especially for topical or ophthalmic applications, but oral formulations usually require prescriptions.
What are the key safety concerns?
Gastrointestinal bleeding, cardiovascular risk, and renal impairment associated with NSAIDs.
Are there pipeline drugs related to flurbiprofen?
Yes, research focuses on novel formulations, nano-drug delivery systems, and combination therapies.
What competitive advantages could new formulations offer?
Extended duration of action, reduced systemic side effects, and patent protection.
References
[1] MarketsandMarkets. (2022). NSAID market forecast and analysis.
[2] FDA. (2022). Regulatory status of NSAID ophthalmic drugs.
[3] European Medicines Agency. (2021). Product approvals and guidelines.
[4] Global Data. (2022). Market share and competitive landscape report.
[5] Novartis. (2021). Pipeline and research initiatives in NSAID formulations.
